Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Hamill John P. has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Mar 16, 2026.
On the most recent filing, Hamill John P. is listed as SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc. Inside the rolling window, Hamill John P. reported 2 open-market purchases totaling $11K in APRE and no open-market sales. The largest disclosed transaction in the window is a purchase of 5,000 APRE shares on Dec 10, 2025, worth $6K.
Companies traded
Other insiders at APRE
Insider Buying
$11K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Hamill John P. made?
Hamill John P. has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.
Which companies does Hamill John P. trade?
Hamill John P. has filed SEC Form 4 disclosures for 1 company, including APRE.
When was Hamill John P.'s most recent SEC Form 4 filing?
Hamill John P.'s most recent SEC Form 4 filing on Tracefour is dated Mar 16, 2026.
What is Hamill John P.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Hamill John P. is listed as SrVP/CFO/Prin Fin & Acct Ofcr.
What is Hamill John P.'s total buy and sell value in the current window?
Inside the rolling retention window, Hamill John P. bought $11K and sold $0 based on SEC Form 4 filings.
What was Hamill John P.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 5,000 APRE shares on 2025-12-10, worth $6K, per SEC Form 4 filings.